---
title: "12 Health Care Stocks Moving In Monday's Pre-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296107663.md"
description: "In Monday's pre-market session, health care stocks showed mixed movements. Gainers included INVO Fertility (+163.4%), GlucoTrack (+35.62%), and OmniAb (+22.49%). Losers featured EyePoint (-61.7%), Apimeds Pharmaceuticals (-30.11%), and IM Cannabis (-27.61%), with declines often linked to recent Q2 or Q3 earnings reports."
datetime: "2026-08-17T12:06:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296107663.md)
  - [en](https://longbridge.com/en/news/296107663.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296107663.md)
---

# 12 Health Care Stocks Moving In Monday's Pre-Market Session

### Gainers

-   **INVO Fertility** (NASDAQ:IVF) shares increased by 163.4% to $2.56 during Monday's pre-market session. The company's market cap stands at $1.7 million.
-   **GlucoTrack** (NASDAQ:GCTK) shares moved upwards by 35.62% to $0.5. The company's market cap stands at $2.8 million.
-   **OmniAb** (NASDAQ:OABI) shares moved upwards by 22.49% to $4.14. The company's market cap stands at $490.0 million.
-   **Anbio Biotechnology** (NASDAQ:NNNN) shares increased by 20.13% to $10.5. The market value of their outstanding shares is at $383.6 million.
-   **Quantum BioPharma** (NASDAQ:QNTM) shares increased by 18.42% to $4.5. The market value of their outstanding shares is at $24.3 million.
-   **Ocular Therapeutix** (NASDAQ:OCUL) shares rose 11.35% to $11.18. The market value of their outstanding shares is at $2.2 billion.

### Losers

-   **EyePoint** (NASDAQ:EYPT) stock declined by 61.7% to $5.64 during Monday's pre-market session. The market value of their outstanding shares is at $1.2 billion.
-   **Apimeds Pharmaceuticals** (AMEX:APUS) shares declined by 30.11% to $3.18. The company's market cap stands at $6.8 million. As per the press release, Q2 earnings came out yesterday.
-   **IM Cannabis** (NASDAQ:IMCC) shares declined by 27.61% to $0.09. The market value of their outstanding shares is at $1.1 million. As per the news, the Q2 earnings report came out 2 days ago.
-   **Adial Pharmaceuticals** (NASDAQ:ADIL) stock declined by 22.62% to $3.08. The company's market cap stands at $8.7 million. The company's, Q2 earnings came out yesterday.
-   **Citius Oncology** (NASDAQ:CTOR) shares declined by 18.67% to $0.74. The company's market cap stands at $84.5 million. The company's, Q3 earnings came out yesterday.
-   **iTonic Holdings** (NASDAQ:ITOC) shares decreased by 17.5% to $0.26. The market value of their outstanding shares is at $5.3 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [GCTK.US](https://longbridge.com/en/quote/GCTK.US.md)
- [EYPT.US](https://longbridge.com/en/quote/EYPT.US.md)
- [IMCC.US](https://longbridge.com/en/quote/IMCC.US.md)
- [OABI.US](https://longbridge.com/en/quote/OABI.US.md)
- [APUS.US](https://longbridge.com/en/quote/APUS.US.md)
- [IVF.US](https://longbridge.com/en/quote/IVF.US.md)
- [NNNN.US](https://longbridge.com/en/quote/NNNN.US.md)
- [QNTM.US](https://longbridge.com/en/quote/QNTM.US.md)
- [OCUL.US](https://longbridge.com/en/quote/OCUL.US.md)
- [ADIL.US](https://longbridge.com/en/quote/ADIL.US.md)
- [CTOR.US](https://longbridge.com/en/quote/CTOR.US.md)
- [ITOC.US](https://longbridge.com/en/quote/ITOC.US.md)
- [OABIW.US](https://longbridge.com/en/quote/OABIW.US.md)

## Related News & Research

- [EYPT: DURAVYU reduced treatment burden by 42% and maintained strong safety in wet AMD](https://longbridge.com/en/news/296109785.md)
- [EyePoint's eye drug misses main goal in late-stage trial](https://longbridge.com/en/news/296096290.md)
- [EyePoint rebounds after selloff despite multiple downgrades](https://longbridge.com/en/news/296243335.md)
- [Glucotrack regains Nasdaq stockholders’ equity compliance, secures continued listing](https://longbridge.com/en/news/296101788.md)
- [EyePoint says Phase 3 LUGANO trial of DURAVYU in wet AMD misses primary endpoint](https://longbridge.com/en/news/296094908.md)